Long-term efficacy and safety of a tetravalent dengue vaccine (TAK-003): 4·5-year results from a phase 3, randomised, double-blind, placebo-controlled trial | Synapse
January 21, 2024Open Access
Long-term efficacy and safety of a tetravalent dengue vaccine (TAK-003): 4·5-year results from a phase 3, randomised, double-blind, placebo-controlled trial
Key Points
Key points are not available for this paper at this time.
Abstract
For the Portuguese, Spanish translations and plain language summary of the abstract see Supplementary Materials section.